Join the cellular immunotherapy revolution this September!
The CAR-TCR drug development field has achieved huge success over the past year with regulatory approval in the US, Europe, Japan and Australia proving the potential these drugs have to successfully cure patients around the globe.
Returning to Boston for the 5th year, the CAR-TCR Summit promises to provide you with one dedicated, all-inclusive forum to advance the clinical and commercial development of CAR and TCR therapies.
Learn from 150 of the best speakers from 99 leading companies
Over 4 days, with 6 dedicated tracks analyzing the challenges and opportunities from bench to bedside, join industry leaders from Novartis, Fate Therapeutics, Cellectis and many more to discuss how to optimize the durability, persistence and targeting of approved and novel therapies to reduce relapse rates and overcome toxicity.
Network with 1000 Senior Level Industry Experts
If you are a dedicated drug developer committed to engineering a cancer-free world, join your community to devise innovative strategies to tackle all forms of cancer through maximizing the potential of genetically reprogrammed immune cells.
"The CAR-TCR summit is an ideal size and attracts the key players in the field. Good opportunity for networking and getting the relevant updates about progress in the space."
"This meeting is increasingly becoming the venue for significant breaking news in the field"
"This is a best in class and top summit in the CAR-TCR area which is an invaluable asset to both industry and academia"
University of Pennsylvania